Axion’s MEA systems can model complex brain activity and heartbeats in a dish. As a result, toxicity and efficacy can be assessed earlier in the drug development process, and with greater sensitivity and accuracy. These comprehensive system-level evaluations provide an in vitro solution to reducing animal testing, a key objective of the Tox21 and REACH initiatives.
Axion’s MEA systems provide a label-free in vitro platform for direct measurement of electrical activity in neurons and cardiomyocytes, while the efficiency and convenience of Axion’s standard MEA plates facilitate use for screening-level applications. The large number of electrodes per well reveals detailed information about systems-level signal propogation.
Axion Releases Teaser Trailer for AxIS 2.0
Atlanta, GA June 30, 2014; Axion Biosystems is pleased to present a light-hearted sneak preview of our upcoming software release, AxIS 2.0. New features include turnkey cardiac pacing, advanced neural metrics, and enhanced real-time signal processing.
Watch the Video
Axion BioSystems Announces Strategic Distribution Partnership with Nanion in Europe and China
Atlanta, GA June 17, 2014; Axion BioSystems, developer of the first high-throughput microelectrode array (MEA) system and Nanion Technologies, a leading provider of automated patch clamp platforms, announce a distribution partnership in Europe and China. Nanion will immediately carry Axion’s MEA-products, supporting a broad range of biomedical research applications.
View Press Release